The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.
Gregory Russell Pond
No relevant relationships to disclose
Joaquim Bellmunt
Research Funding - Pierre Fabre Medicament
Ronan Fougeray
Employment or Leadership Position - Pierre Fabre Medicament
Toni K. Choueiri
Research Funding - AstraZeneca
Angela Q. Qu
Research Funding - AstraZeneca
Yacine Salhi
Employment or Leadership Position - Pierre Fabre Medicament
Research Funding - Bristol-Myers Squibb; Lilly
Guenter Niegisch
Research Funding - Bristol-Myers Squibb; Lilly
Peter Albers
Research Funding - Bristol-Myers Squibb; Lilly
Giuseppe Di Lorenzo
No relevant relationships to disclose
Matt D. Galsky
No relevant relationships to disclose
Andrea Necchi
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Guru Sonpavde
No relevant relationships to disclose